Exploring Patient Adherence to Post-Surgical Follow-Up in Pelvic Endometriosis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Assessment of Symptoms during Follow-Up
2.3. Statistical Analyses
3. Results
CIRENDO
- The physical functioning segment had a significantly lower score for group A compared to group B before surgery (60.8 vs. 71.7) with lower postoperative improvement (8 vs. 7.6)
- Role limitations due to physical functioning were reported at 27.6 for group A and 46.4 for group B prior to surgery, with higher postoperative improvement in the case of group A (16.9 vs. 13.7)
- (47.3 vs. 53.5; 46.6 vs. 56.4), but with no statistical difference in post-surgical improvement.
- Pain level score improvement was lower for group A, 10.5 (60.0–49.5 number of patients) vs. 18.8 (67.1–48.3 number of patients), and was statistically significant.
- There were no differences in the score increase for energy levels between the two groups; however, there were significantly lower scores both before and after surgery for group A.
- Social functioning was reported to be significantly lower for group A (before surgery, 49.2 vs. 54.5; 1 year after surgery, 58.2 vs. 67.1).
- Role limitations due to emotional involvement before and after surgery had overall lower scores for group A (before surgery, 44.2 vs. 52.4; 1 year after surgery, 57.6 vs. 64.9) but with no statistical difference in the post-surgical improvement.
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Zhang, P.; Wang, G. Progesterone Resistance in Endometriosis: Current Evidence and Putative Mechanisms. Int. J. Mol. Sci. 2023, 24, 6992. [Google Scholar] [CrossRef] [PubMed]
- DiVasta, A.D.; Vitonis, A.F.; Laufer, M.R.; Missmer, S.A. Spectrum of symptoms in women diagnosed with endometriosis during adolescence vs. adulthood. Am. J. Obstet. Gynecol. 2018, 218, 324.e1–324.e11. [Google Scholar] [CrossRef] [PubMed]
- Keckstein, J.; Becker, C.M.; Canis, M.; Feki, A.; Grimbizis, G.F.; Hummelshoj, L.; Nisolle, M.; Roman, H.; Saridogan, E.; Tanos, V.; et al. Recommendations for the surgical treatment of endometriosis Part 2: Deep endometriosis. Facts Views Vis. Obgyn 2020, 11, 269–297. [Google Scholar]
- Vermeulen, N.; Abrao, M.S.; Einarsson, J.I.; Horne, A.W.; Johnson, N.P.; Lee, T.T.M.; Missmer, S.; Petrozza, J.; Tomassetti, C.; Zondervan, K.T.; et al. Endometriosis Classification, Staging and Reporting Systems: A Review on the Road to a Universally Accepted Endometriosis Classification. J. Minim. Invasive Gynecol. 2021, 28, 1822–1848. [Google Scholar] [CrossRef]
- Almeida Asencio, F.; Ribeiro, H.A.; Ayrosa Ribeiro, P. Symptomatic endometriosis developing several years after menopause in the absence of increased circulating estrogen concentrations: A systematic review and seven case reports. Gynecol. Surg. 2019, 16, 3. [Google Scholar] [CrossRef] [Green Version]
- Rafique, S.; Decherney, A.H. Medical Management of Endometriosis. Clin. Obstet. Gynecol. 2017, 60, 485–496. [Google Scholar] [CrossRef]
- Patel, B.G.; Rudnicki, M.; Yu, J.; Shu, Y.; Taylor, R.N. Progesterone resistance in endometriosis: Origins, consequences and interventions. Acta Obstet. Gynecol. Scand. 2017, 96, 623–632. [Google Scholar] [CrossRef] [Green Version]
- Reis, F.M.; Coutinho, L.M.; Vannuccini, S.; Batteux, F.; Chapron, C.; Petraglia, F. Progesterone receptor ligands for the treatment of endometriosis: The mechanisms behind therapeutic success and failure. Hum. Reprod. Update 2020, 26, 565–585. [Google Scholar] [CrossRef]
- Vannuccini, S.; Clemenza, S.; Rossi, M.; Petraglia, F. Hormonal treatments for endometriosis: The endocrine background. Rev. Endocr. Metab. Disord. 2022, 23, 333–355. [Google Scholar] [CrossRef]
- Vercellini, P.; Bandini, V.; Buggio, L.; Barbara, G.; Berlanda, N.; Dridi, D.; Frattaruolo, M.P.; Somigliana, E. Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: Why not. Hum. Reprod. Open. 2023, 2023, hoad008. [Google Scholar] [CrossRef]
- Abdul Karim, A.K.; Shafiee, M.N.; Abd Aziz, N.H.; Omar, M.H.; Abdul Ghani, N.A.; Lim, P.S.; Md Zin, R.R.; Mokhtar, N. Reviewing the role of progesterone therapy in endometriosis. Gynecol. Endocrinol. 2019, 35, 10–16. [Google Scholar] [CrossRef] [PubMed]
- Donnez, J.; Dolmans, M.M. Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review. J. Clin. Med. 2021, 10, 1085. [Google Scholar] [CrossRef] [PubMed]
- Walankiewicz, M.; Grywalska, E.; Polak, G.; Korona-Glowniak, I.; Witt, E.; Surdacka, A.; Kotarski, J.; Rolinski, J. The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters. Mediat. Inflamm. 2018, 2018, 7041342. [Google Scholar] [CrossRef] [Green Version]
- Kamrani, S.; Amirchaghmaghi, E.; Ghaffari, F.; Shahhoseini, M.; Ghaedi, K. Altered gene expression of VEGF, IGFs and H19 lncRNA and epigenetic profile of H19-DMR region in endometrial tissues of women with endometriosis. Reprod. Health 2022, 19, 100. [Google Scholar] [CrossRef] [PubMed]
- Brubel, R.; Bokor, A.; Pohl, A.; Schilli, G.K.; Szereday, L.; Bacher-Szamuel, R.; Rigo, J.; Polgar, B. Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. Fertil. Steril. 2017, 108, 1016–1025.e2. [Google Scholar] [CrossRef] [Green Version]
- Leonardi, M.; Gibbons, T.; Armour, M.; Wang, R.; Glanville, E.; Hodgson, R.; Cave, A.E.; Ong, J.; Tong, Y.Y.F.; Jacobson, T.Z.; et al. When to Do Surgery and When Not to Do Surgery for Endometriosis: A Systematic Review and Meta-analysis. J. Minim. Invasive Gynecol. 2020, 27, 390–407.e3. [Google Scholar] [CrossRef]
- Casper, R.F. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil. Steril. 2017, 107, 533–536. [Google Scholar] [CrossRef] [Green Version]
- Koning, R.; Zwart, G.; Dahan, A.; Jansen, F.W.; Blikkendaal, M.; Twijnstra, A. Esketamine in the treatment of chronic endometriosis-induced pain: A case report. J. Endometr. Pelvic Pain Disord. 2023, 15, 49–52. [Google Scholar] [CrossRef]
- Tennfjord, M.K.; Gabrielsen, R.; Tellum, T. Effect of physical activity and exercise on endometriosis-associated symptoms: A systematic review. BMC Womens Health 2021, 21, 355. [Google Scholar] [CrossRef]
- Hudson, Q.J.; Perricos, A.; Wenzl, R.; Yotova, I. Challenges in uncovering non-invasive biomarkers of endometriosis. Exp. Biol. Med. 2020, 245, 437–447. [Google Scholar] [CrossRef]
- Bouquet de Joliniere, J.; Major, A.; Ayoubi, J.M.; Cabry, R.; Khomsi, F.; Lesec, G.; Frydman, R.; Feki, A. It Is Necessary to Purpose an Add-on to the American Classification of Endometriosis? This Disease Can Be Compared to a Malignant Proliferation While Remaining Benign in Most Cases. EndoGram® Is a New Profile Witness of Its Evolutionary Potential. Front. Surg. 2019, 6, 27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nisenblat, V.; Bossuyt, P.M.; Shaikh, R.; Farquhar, C.; Jordan, V.; Scheffers, C.S.; Mol, B.W.; Johnson, N.; Hull, M.L. Blood biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst. Rev. 2016, 2016, CD012179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vanhie, A.O.D.; Peterse, D.; Beckers, A.; Cuéllar, A.; Fassbender, A.; Meuleman, C.; Mestdagh, P.; D’Hooghe, T. Plasma miRNAs as biomarkers for endometriosis. Hum. Reprod. 2019, 34, 1650–1660. [Google Scholar] [CrossRef] [PubMed]
- Ahn, S.H.; Singh, V.; Tayade, C. Biomarkers in endometriosis: Challenges and opportunities. Fertil. Steril. 2017, 107, 523–532. [Google Scholar] [CrossRef] [Green Version]
- Grandi, G.; Barra, F.; Ferrero, S.; Sileo, F.G.; Bertucci, E.; Napolitano, A.; Facchinetti, F. Hormonal contraception in women with endometriosis: A systematic review. Eur. J. Contracept. Reprod. Health Care 2019, 24, 61–70. [Google Scholar] [CrossRef] [PubMed]
- Morotti, M.; Sozzi, F.; Remorgida, V.; Venturini, P.L.; Ferrero, S. Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014, 183, 188–192. [Google Scholar] [CrossRef]
- Pluchino, N.; Mamillapalli, R.; Wenger, J.M.; Ramyead, L.; Drakopoulos, P.; Tille, J.C.; Taylor, H.S. Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis. Fertil. Steril. 2020, 113, 1224–1231.e1. [Google Scholar] [CrossRef]
- Clemenza, S.; Sorbi, F.; Noci, I.; Capezzuoli, T.; Turrini, I.; Carriero, C.; Buffi, N.; Fambrini, M.; Petraglia, F. From pathogenesis to clinical practice: Emerging medical treatments for endometriosis. Best Pract. Res. Clin. Obs. Gynaecol. 2018, 51, 92–101. [Google Scholar] [CrossRef]
- Lunde, C.E.; Szabo, E.; Holmes, S.A.; Borsook, D.; Sieberg, C.B. Commentary: Novel Use of Offset Analgesia to Assess Adolescents and Adults with Treatment Resistant Endometriosis-Associated Pain. J. Pain Res. 2020, 13, 2775–2782. [Google Scholar] [CrossRef]
- Capezzuoli, T.; Vannuccini, S.; Mautone, D.; Sorbi, F.; Chen, H.; Reis, F.M.; Ceccaroni, M.; Petraglia, F. Long-term hormonal treatment reduces repetitive surgery for endometriosis recurrence. Reprod. Biomed. Online 2021, 42, 451–456. [Google Scholar] [CrossRef]
- Moon, H.S.; Shim, J.E.; Lee, S.R.; Jeong, K. The Comparison of Robotic Single-Site Surgery to Single-Port Laparoendoscopic Surgery for the Treatment of Advanced-Stage Endometriosis. J. Laparoendosc. Adv. Surg. Tech. A 2018, 28, 1483–1488. [Google Scholar] [CrossRef] [PubMed]
- Kho, R.M.; Andres, M.P.; Borrelli, G.M.; Neto, J.S.; Zanluchi, A.; Abrão, M.S. Surgical treatment of different types of endometriosis: Comparison of major society guidelines and preferred clinical algorithms. Best Pract. Res. Clin. Obs. Gynaecol. 2018, 51, 102–110. [Google Scholar] [CrossRef] [PubMed]
- Restaino, S.; Mereu, L.; Finelli, A.; Spina, M.R.; Marini, G.; Catena, U.; Turco, L.C.; Moroni, R.; Milani, M.; Cela, V.; et al. Robotic surgery vs. laparoscopic surgery in patients with diagnosis of endometriosis: A systematic review and meta-analysis. J. Robot. Surg. 2020, 14, 687–694. [Google Scholar] [CrossRef]
- Bafort, C.; Beebeejaun, Y.; Tomassetti, C.; Bosteels, J.; Duffy, J.M. Laparoscopic surgery for endometriosis. Cochrane Database Syst. Rev. 2020, 10, CD011031. [Google Scholar] [CrossRef]
- Colette, S.; Donnez, J. Are aromatase inhibitors effective in endometriosis treatment. Expert Opin. Investig. Drugs 2011, 20, 917–931. [Google Scholar] [CrossRef] [PubMed]
- Bougie, O.; McClintock, C.; Pudwell, J.; Brogly, S.B.; Velez, M.P. Long-term follow-up of endometriosis surgery in Ontario: A population-based cohort study. Am. J. Obstet. Gynecol. 2021, 225, 270.e1–270.e19. [Google Scholar] [CrossRef] [PubMed]
- Martínez-Zamora, M.A.; Coloma, J.L.; Gracia, M.; Rius, M.; Castelo-Branco, C.; Carmona, F. Long-term Follow-up of Sexual Quality of Life after Laparoscopic Surgery in Patients with Deep Infiltrating Endometriosis. J. Minim. Invasive Gynecol. 2021, 28, 1912–1919. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.S.; Gude, K.; Perdeaux, E.; Gattrell, W.T.; Becker, C.M. Surgical Outcomes in Patients With Endometriosis: A Systematic Review. J. Obstet. Gynaecol. Can. 2020, 42, 881–888.e11. [Google Scholar] [CrossRef]
- Healey, M.; Cheng, C.; Kaur, H. To excise or ablate endometriosis? A prospective randomized double-blinded trial after 5-year follow-up. J. Minim. Invasive Gynecol. 2014, 21, 999–1004. [Google Scholar] [CrossRef]
S1 | S3 | S5 | S7 | |||||||
---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | p | ||
No. patients | Surgeries 2538 | 453 | 25.42 | 528 | 29.63 | 445 | 24.97 | 356 | 19.98 | |
Marital status | Married | 152 | 33.85 | 178 | 33.97 | 163 | 36.88 | 149 | 41.97 | <0.000 |
Celibate | 70 | 15.59 | 72 | 13.74 | 80 | 18.10 | 65 | 18.31 | ||
Divorced | 11 | 2.45 | 12 | 2.29 | 16 | 3.62 | 14 | 3.94 | ||
Widowed | 24 | 5.35 | 12 | 2.29 | 6 | 1.36 | 4 | 1.13 | ||
Concubinage | 180 | 40.09 | 232 | 44.27 | 166 | 37.56 | 118 | 33.24 | ||
Other | 12 | 2.67 | 18 | 3.44 | 11 | 2.49 | 5 | 1.41 | ||
Employment | Employed | 370 | 82.96 | 432 | 82.29 | 364 | 82.54 | 295 | 84.05 | 0.001 |
Housewife | 16 | 3.59 | 14 | 2.67 | 20 | 4.54 | 15 | 4.27 | ||
Student | 9 | 2.02 | 18 | 3.43 | 31 | 7.03 | 15 | 4.27 | ||
Unemployed | 51 | 11.43 | 61 | 11.62 | 26 | 5.9 | 26 | 7.41 | ||
Mental status | Psych. Dis. | 155 | 27.00 | 169 | 29.44 | 136 | 23.69 | 114 | 19.86 | >0.05 |
Anxiety | 118 | 27.31 | 128 | 29.63 | 99 | 22.92 | 87 | 20.14 | ||
Depression | 55 | 24.77 | 74 | 33.33 | 55 | 24.77 | 38 | 17.12 | ||
Insomnia | 79 | 25.99 | 89 | 29.28 | 79 | 25.99 | 57 | 18.75 | ||
Panic attacks | 35 | 29.66 | 34 | 28.81 | 33 | 27.97 | 16 | 13.56 | ||
rAFS | I | 49 | 11.19 | 66 | 12.74 | 75 | 16.93 | 49 | 13.96 | 0.001 |
II | 82 | 18.72 | 84 | 16.22 | 86 | 19.41 | 49 | 13.96 | ||
III | 67 | 15.30 | 91 | 17.57 | 94 | 21.22 | 87 | 24.79 | ||
IV | 240 | 54.79 | 277 | 53.47 | 188 | 42.44 | 166 | 47.29 | ||
Infertility | Primary | 98 | 62.42 | 106 | 55.79 | 71 | 52.99 | 49 | 47.12 | 0.09 |
Secondary | 59 | 37.58 | 84 | 44.21 | 63 | 47.01 | 55 | 52.88 | ||
Pregnancy status | Desire before surgery | 243 | 53.64 | 299 | 56.63 | 213 | 47.87 | 154 | 43.06 | 0.064 |
PMA after 1 year | 42 | 9.28 | 44 | 8.33 | 38 | 8.54 | 24 | 6.73 | >0.05 | |
Pregnancy after 1 year | 92 | 20.31 | 89 | 16.86 | 96 | 21.57 | 76 | 21.35 | <0.05 | |
Delivery after 1 year | 34 | 7.51 | 26 | 4.92 | 23 | 5.17 | 14 | 3.93 | >0.05 | |
PMA after 3 years | 91 | 17.24 | 63 | 14.16 | 43 | 12.08 | <0.05 | |||
Pregnancy after 3 years | 168 | 31.82 | 139 | 31.24 | 104 | 29.21 | <0.05 | |||
Delivery after 3 years | 143 | 27.08 | 127 | 28.54 | 93 | 26.12 | <0.05 | |||
PMA after 5 years | 10 | 2.23 | 5 | 1.4 | >0.05 | |||||
Pregnancy after 5 years | 25 | 5.62 | 28 | 7.87 | >0.05 | |||||
Delivery after 5 years | 21 | 4.72 | 25 | 7.02 | >0.05 | |||||
PMA after 7 years | 1 | 0.28 | >0.05 | |||||||
Pregnancy after 7 years | 14 | 3.93 | >0.05 | |||||||
Delivery after 7 years | 10 | 2.81 | >0.05 | |||||||
Digestive involvement | 267 | 58.94 | 278 | 52.65 | 177 | 39.78 | 127 | 35.67 | <0.05 | |
Urologic involvement | 76 | 16.78 | 78 | 14.77 | 47 | 10.56 | 54 | 15.17 | >0.05 |
Patients Lost to Follow-Up after 1 Year | Before Surgery | S1 | S3 | S5 | S7 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | p | ||
Menstrual cycles | Pain | 432 | 95.6 | 135 | 31.8 | <0.05 | ||||||
Urinary symptoms | 145 | 34.0 | 26 | 20.5 | <0.05 | |||||||
Pain treatment | 379 | 88.6 | 87 | 66.9 | <0.05 | |||||||
Pain intensity (no treatment) | 8.48 | 6.37 | <0.05 | |||||||||
Pain intensity (with treatment) | 4.84 | 3.13 | <0.05 | |||||||||
Intercourse | Pain | 354 | 78.3 | 160 | 39.5 | <0.05 | ||||||
Limitations | 334 | 95.2 | 134 | 84.3 | <0.05 | |||||||
Pain intensity (no treatment) | 6.38 | 5.29 | <0.05 | |||||||||
Pain intensity (with treatment) | 4.61 | 3.88 | >0.05 | |||||||||
Pain associated to endometriosis | 373 | 82.9 | 227 | 55.1 | <0.05 | |||||||
Pain treatment | 259 | 70.8 | 117 | 54.4 | <0.05 | |||||||
Pain intensity (no treatment) | 6.68 | 5.28 | <0.05 | |||||||||
Pain intensity (with treatment) | 3.79 | 2.76 | >0.05 | |||||||||
SF36 | Physical functioning | 60.8 | 64.6 | >0.05 | ||||||||
Role limitations due to phys. Funct | 27.6 | 44.5 | <0.05 | |||||||||
Pain | 49.5 | 60.0 | <0.05 | |||||||||
General health | 47.3 | 46.6 | >0.05 | |||||||||
Energy/fatigue | 32.9 | 37.7 | <0.05 | |||||||||
Social functioning | 49.2 | 58.2 | <0.05 | |||||||||
Role limitations due to emo. | 44.2 | 57.6 | <0.05 | |||||||||
KESS | 12.7 | 10.6 | >0.05 | |||||||||
Giqli | 83.9 | 98.9 | <0.05 |
Patients Lost to Follow-Up after 1 Year (Group A) | Patients Not Lost to Follow Up (Group B) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Before Surgery | S1 | Before Surgery | S1 | |||||||
n | % | n | % | n | % | n | % | p | ||
Menstrual cycles | Pain | 432 | 95.6 | 135 | 31.8 | 330 | 93.5 | 132 | 37.5 | <0.05 |
Urinary symptoms | 145 | 34.0 | 26 | 20.5 | 76 | 23.6 | 15 | 11.9 | <0.05 | |
Pain treatment | 379 | 88.6 | 87 | 66.9 | 281 | 87.3 | 98 | 74.8 | <0.05 | |
Pain intensity (no treatment) | 8.48 | 6.37 | 7.89 | 5.99 | >0.05 | |||||
Pain intensity (with treatment) | 4.84 | 3.13 | 4.16 | 2.88 | >0.05 | |||||
Intercourse | Pain | 354 | 78.3 | 160 | 39.5 | 244 | 68.5 | 129 | 37.0 | >0.05 |
Limitations | 334 | 95.2 | 134 | 84.3 | 216 | 92.4 | 111 | 87.4 | <0.05 | |
Pain intensity (no treatment) | 6.38 | 5.29 | 5.76 | 4.64 | >0.05 | |||||
Pain intensity (with treatment) | 4.61 | 3.88 | 4.13 | 3.74 | >0.05 | |||||
Pain associated to endometriosis | 373 | 82.9 | 227 | 55.1 | 239 | 67.9 | 183 | 52.6 | <0.05 | |
Pain treatment | 259 | 70.8 | 117 | 54.4 | 145 | 64.4 | 115 | 66.9 | <0.05 | |
Pain intensity (no treatment) | 6.68 | 5.28 | 6.18 | 5.16 | >0.05 | |||||
Pain intensity (with treatment) | 3.79 | 2.76 | 3.66 | 3.04 | <0.05 | |||||
SF36 | Physical functioning | 60.8 | 64.6 | 71.7 | 79.3 | <0.05 | ||||
Role limitations due to phys. Funct. | 27.6 | 44.5 | 46.4 | 60.1 | >0.05 | |||||
Pain | 49.5 | 60.0 | 48.3 | 67.1 | <0.05 | |||||
General health | 47.3 | 46.6 | 53.5 | 56.4 | >0.05 | |||||
Energy/fatigue | 32.9 | 37.7 | 36.6 | 43.7 | >0.05 | |||||
Social functioning | 49.2 | 58.2 | 54.5 | 67.1 | <0.05 | |||||
Role limitations due to emo. | 44.2 | 57.6 | 52.4 | 64.9 | >0.05 | |||||
KESS | 12.7 | 10.6 | 11.2 | 10.2 | <0.05 | |||||
Giqli | 83.9 | 98.9 | 93.1 | 105.2 | >0.05 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Szabo, T.; Mitranovici, M.-I.; Crisan, A.; Melinte, I.M.; Cotrus, T.; Tudorache, V.; Moraru, L.; Moraru, R.; Micu, R. Exploring Patient Adherence to Post-Surgical Follow-Up in Pelvic Endometriosis. Medicina 2023, 59, 1210. https://doi.org/10.3390/medicina59071210
Szabo T, Mitranovici M-I, Crisan A, Melinte IM, Cotrus T, Tudorache V, Moraru L, Moraru R, Micu R. Exploring Patient Adherence to Post-Surgical Follow-Up in Pelvic Endometriosis. Medicina. 2023; 59(7):1210. https://doi.org/10.3390/medicina59071210
Chicago/Turabian StyleSzabo, Tamas, Melinda-Ildiko Mitranovici, Andrada Crisan, Ioana Marta Melinte, Teodora Cotrus, Vlad Tudorache, Liviu Moraru, Raluca Moraru, and Romeo Micu. 2023. "Exploring Patient Adherence to Post-Surgical Follow-Up in Pelvic Endometriosis" Medicina 59, no. 7: 1210. https://doi.org/10.3390/medicina59071210